These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38956614)

  • 1. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
    Braimoh T; Burrone E; Gore C; Vijayaraghavan P
    Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study.
    Morin S; Moak HB; Bubb-Humfryes O; von Drehle C; Lazarus JV; Burrone E
    Lancet Public Health; 2022 Feb; 7(2):e169-e176. PubMed ID: 34710359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements.
    Griffen EJ; Boulet P; ;
    Wellcome Open Res; 2024; 9():374. PubMed ID: 39184131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities.
    Morin S; Segafredo G; Piccolis M; Das A; Das M; Loffredi N; Larbi A; Mwamelo K; Villanueva E; Nobre S; Burrone E
    Lancet Glob Health; 2023 Jan; 11(1):e145-e154. PubMed ID: 36455593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMPULSORY LICENSING IN CONTEXT OF THE COVID-19 PANDEMIC AS A TOOL FOR ENSURING THE BALANCE BETWEEN RIGHTS-HOLDERS' AND SOCIETY'S INTERESTS.
    Chepys O
    Georgian Med News; 2020 Nov; (308):160-165. PubMed ID: 33395660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution.
    Agampodi S; Mogeni OD; Chandler R; Pansuriya M; Kim JH; Excler JL
    Expert Rev Vaccines; 2024; 23(1):761-772. PubMed ID: 39167221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.
    Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Intellectual Property the COVID-19 Bad Guy? Lessons We Could Learn from the Pandemic.
    Lawson C
    J Law Med; 2023 Dec; 30(3):538-554. PubMed ID: 38332594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic.
    Tietze F; Vimalnath P; Aristodemou L; Molloy J
    IEEE Trans Eng Manag; 2022 Oct; 69(5):2039-2056. PubMed ID: 35938060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.